127 related articles for article (PubMed ID: 11427889)
1. Interhelical hydrogen bonds in the CFTR membrane domain.
Therien AG; Grant FE; Deber CM
Nat Struct Biol; 2001 Jul; 8(7):597-601. PubMed ID: 11427889
[TBL] [Abstract][Full Text] [Related]
2. Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations.
Choi MY; Cardarelli L; Therien AG; Deber CM
Biochemistry; 2004 Jun; 43(25):8077-83. PubMed ID: 15209503
[TBL] [Abstract][Full Text] [Related]
3. Role of the extracellular loop in the folding of a CFTR transmembrane helical hairpin.
Wehbi H; Rath A; Glibowicka M; Deber CM
Biochemistry; 2007 Jun; 46(24):7099-106. PubMed ID: 17516627
[TBL] [Abstract][Full Text] [Related]
4. Transmembrane domain of cystic fibrosis transmembrane conductance regulator: design, characterization, and secondary structure of synthetic peptides m1-m6.
Wigley WC; Vijayakumar S; Jones JD; Slaughter C; Thomas PJ
Biochemistry; 1998 Jan; 37(3):844-53. PubMed ID: 9454574
[TBL] [Abstract][Full Text] [Related]
5. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
Loo TW; Clarke DM
Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
[TBL] [Abstract][Full Text] [Related]
6. Expression and purification of two hydrophobic double-spanning membrane proteins derived from the cystic fibrosis transmembrane conductance regulator.
Therien AG; Glibowicka M; Deber CM
Protein Expr Purif; 2002 Jun; 25(1):81-6. PubMed ID: 12071702
[TBL] [Abstract][Full Text] [Related]
7. Positional dependence of non-native polar mutations on folding of CFTR helical hairpins.
Wehbi H; Gasmi-Seabrook G; Choi MY; Deber CM
Biochim Biophys Acta; 2008 Jan; 1778(1):79-87. PubMed ID: 17949679
[TBL] [Abstract][Full Text] [Related]
8. Polar residues in membrane domains of proteins: molecular basis for helix-helix association in a mutant CFTR transmembrane segment.
Partridge AW; Melnyk RA; Deber CM
Biochemistry; 2002 Mar; 41(11):3647-53. PubMed ID: 11888281
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for misfolding at a disease phenotypic position in CFTR: comparison of TM3/4 helix-loop-helix constructs with TM4 peptides.
Mulvihill CM; Deber CM
Biochim Biophys Acta; 2012 Jan; 1818(1):49-54. PubMed ID: 21996038
[TBL] [Abstract][Full Text] [Related]
10. An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator.
Tector M; Hartl FU
EMBO J; 1999 Nov; 18(22):6290-8. PubMed ID: 10562541
[TBL] [Abstract][Full Text] [Related]
11. Biochemical implications of sequence comparisons of the cystic fibrosis transmembrane conductance regulator.
Tan AL; Ong SA; Venkatesh B
Arch Biochem Biophys; 2002 May; 401(2):215-22. PubMed ID: 12054472
[TBL] [Abstract][Full Text] [Related]
12. Stable dimeric assembly of the second membrane-spanning domain of CFTR (cystic fibrosis transmembrane conductance regulator) reconstitutes a chloride-selective pore.
Ramjeesingh M; Ugwu F; Li C; Dhani S; Huan LJ; Wang Y; Bear CE
Biochem J; 2003 Nov; 375(Pt 3):633-41. PubMed ID: 12892562
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing DeltaF508 mutation.
Massiah MA; Ko YH; Pedersen PL; Mildvan AS
Biochemistry; 1999 Jun; 38(23):7453-61. PubMed ID: 10360942
[TBL] [Abstract][Full Text] [Related]
14. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
Cheung JC; Deber CM
Biochemistry; 2008 Feb; 47(6):1465-73. PubMed ID: 18193900
[TBL] [Abstract][Full Text] [Related]
15. A protein sequence that can encode native structure by disfavoring alternate conformations.
Wigley WC; Corboy MJ; Cutler TD; Thibodeau PH; Oldan J; Lee MG; Rizo J; Hunt JF; Thomas PJ
Nat Struct Biol; 2002 May; 9(5):381-8. PubMed ID: 11938353
[TBL] [Abstract][Full Text] [Related]
16. Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease.
Partridge AW; Therien AG; Deber CM
Proteins; 2004 Mar; 54(4):648-56. PubMed ID: 14997561
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
18. Association of the cystic fibrosis transmembrane regulator with CAL: structural features and molecular dynamics.
Piserchio A; Fellows A; Madden DR; Mierke DF
Biochemistry; 2005 Dec; 44(49):16158-66. PubMed ID: 16331976
[TBL] [Abstract][Full Text] [Related]
19. N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel.
Gené GG; Llobet A; Larriba S; de Semir D; Martínez I; Escalada A; Solsona C; Casals T; Aran JM
Hum Mutat; 2008 May; 29(5):738-49. PubMed ID: 18306312
[TBL] [Abstract][Full Text] [Related]
20. Misprocessing of the CFTR protein leads to mild cystic fibrosis phenotype.
Clain J; Lehmann-Che J; Duguépéroux I; Arous N; Girodon E; Legendre M; Goossens M; Edelman A; de Braekeleer M; Teulon J; Fanen P
Hum Mutat; 2005 Apr; 25(4):360-71. PubMed ID: 15776432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
